Ganoderma lucidum polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation

Experimental and Therapeutic Medicine

Volumn 5, Issue 4, 2013, Pages 1117-1122

  Sun, Li Xin ^a   Lin, Zhi Bin ^b   Duan, Xin Suo ^a   Lu, Jie ^a   Ge, Zhi Hua ^a   Li, Min ^b   Xing, En Hong ^a   Lan, Tian Fei ^a   Jiang, Miao Miao ^a   Yang, Ning ^a   Li, Wei Dong ^b  

^a CHENGDE MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

CD71; FasL; Ganoderma lucidum; Lymphocyte activation; Polysaccharides; Tumor

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; CD69 ANTIGEN; CD71 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; FAS LIGAND; GANODERMA LUCIDUM EXTRACT; GANODERMA LUCIDUM POLYSACCHARIDE; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84874632877     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.931     Document Type: Article

References (45)

1. Swann JB and Smyth MJ: Immune surveillance of tumors. J Clin Invest 117: 1137-1146, 2007.
2. Gross S and Walden P: Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett 116: 7-14, 2008.
3. Rabinovich GA, Gabrilovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296, 2007.
4. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15, 2006.
5. Shao BM, Dai H, Xu W, Lin ZB and Gao XM: Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun 323: 133-141, 2004.
6. Chan WK, Cheung CC, Law HK, Lau YL and Chan GC: Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immunostimulatory function. J Hematol Oncol 1: 9, 2008.
7. Amarante MK, Watanabe MA, Conchon-Costa I, Fiori LL, Oda JM, Búfalo MC and Sforcin JM: The effects of propolis on CCL5 and IFN-γ expression by peripheral blood mononuclear cells from leishmaniasis patients. J Pharm Pharmacol 64: 154-160, 2012.
8. Kour K, Sangwan PL, Khan I, Koul S, Sharma SN, Kitchlu S and Bani S: Alcoholic extract of Cicer microphyllum augments Th1 immune response in normal and chronically stressed Swiss albino mice. J Pharm Pharmacol 63: 267-277, 2011
9. Sliva D: Medicinal mushroom Phellinus linteus as an alternative cancer therapy. Exp Ther Med 1: 407-411, 2010.
10. Vermorken AJ, Zhu J, Van de Ven WJ, Cui Y and Fryns JP: Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution. Exp Ther Med 1: 265-269, 2010.
11. Li QQ, Wang G, Reed E, Huang L and Cuff CF: Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol 107: 868-876, 2010.
12. Mishra N, Tiwari S, Vaidya B, Agrawal GP and Vyas SP: Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target 19: 67-78, 2011.
13. Zhong Z, Dong Z, Yang L, Chen X and Gong Z: Inhibition of proliferation of human lung cancer cells by green tea catechins is mediated by upregulation of let-7. Exp Ther Med 4: 267-272, 2012.
14. Yang Y, Jin C, Li H, He Y, Liu Z, Bai L and Dou K: Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. Exp Ther Med 3: 299-303, 2012.
15. Yang X, Hu W, Zhang Q, Wang Y and Sun L: Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol 107:637-42, 2010.
16. Lin ZB and Zhang HN: Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 25: 1387-1395, 2004.
17. You YH and Lin ZB: Protective effects of Ganoderma lucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. Acta Pharmacol Sin 23: 787-791, 2002.
18. Zhang GL, Wang Y H, Ni W, Teng H L and Lin ZB: Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice. World J Gastroenterol 8: 728-733, 2002.
19. Zhang HN, He JH, Yuan L and Lin ZB: In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage. Life Sci 73: 2307-2319, 2003.
20. Zhu XL and Lin ZB: Modulation of cytokines production, granzyme B and perforin in murine CIK cells by Ganoderma lucidum polysaccharides. Carbohydrate Polymers 63: 188-197, 2006.
21. Sun LX, Chen LH, Lin ZB, Qin Y, Zhang JQ, Yang J, Ma J, Ye T and Li WD: Effects of Ganoderma lucidum polysaccharides on IEC-6 cell proliferation, migration and morphology of differentiation benefiting intestinal epithelium healing in vitro. J Pharm Pharmacol 63: 1595-1603, 2011.
22. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XJ, Li M, Xing EH, Jia J, Lan TF and Li WD: Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. J Pharm Pharmacol 63: 725-35, 2011.
23. Sun LX, Lin ZB, Li XJ, Li M, Lu J, Duan XS, Ge ZH, Song YX, Xing EH and Li WD: Promoting effects of Ganoderma lucidum polysaccharides on B16F10 cells to activate lymphocytes. Basic Clin Pharmacol Toxicol 108: 149-154, 2011.
24. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Song YX, Li XJ, Li M, Xing EH, Yang N and Li WD: Stronger cytotoxicity in CTLs with granzyme B and porforin was induced by Ganoderma lucidum polysaccharides acting on B16F10 cells. Biomed Prev Nutr 2: 113-118, 2012. doi:10.1016/j.bionut.2012.01.001
25. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XF, Li XJ, Li M, Xing EH, Song YX, Jia J and Li WD: Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides. J Drug Target 20: 582-592, 2012.
26. Cao LZ and Lin ZB: Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett 83: 163-169, 2002.
27. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH and Lin CH: Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 10: 1057-1062, 2002.
28. Reddy M, Eirikis E, Davis C, Davis HM and Prabhakar U: Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods 293: 127-142, 2004.
29. Whiteside TL: Immune responses to malignancies. J Allergy Clin Immunol 125:S272-S283, 2010.
30. Whiteside TL, Mandapathil M, Szczepanski M and Szajnik M: Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer 98: E25-E31, 2011.
31. Wongkajornsilp A, Luankosolchai RA, Huabprasert S, Chanyavanich V, Tisavipat N and Watanapa P: The observation of immunosuppressor(s) derived from cultured tumor cells and its partial neutralization with OK-432. J Med Assoc Thai 84: 212-122, 2001.
32. Frumento G, Piazza T, Di Carlo E and Ferrini S: Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6: 233-237, 2006.
33. Cortés-Barberena E, González-Márquez H, Gómez-Olivares JL and Ortiz-Muñiz R: Effects of moderate and severe malnutrition in rats on splenic T lymphocyte subsets and activation assessed by flow cytometry. Clin Exp Immunol 152: 585-592, 2008.
34. Testa U, Pelosi E and Peschle C: The transferrin receptor. Crit Rev Oncog 4: 241-276, 1993.
35. Goral S: The three-signal hypothesis of lymphocyte activation/ targets for immunosuppression. Dial Transplant 40: 14-16, 2011.
36. Reicher B and Barda-Saad M: Multiple pathways leading from the T-cell antigen receptor to the actin cytoskeleton network. FEBS Lett 584: 4858-4864, 2010.
37. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R and Lascurain R: Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6: 15-25, 2009.
38. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A and Kiener PA. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 185: 1487-1492, 1997.
39. Sun M, Ames KT, Suzuki I and Fink PJ: The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 177: 1481-1491, 2006.
40. Dzialo-Hatton R, Milbrandt J, Hockett RD Jr and Weaver CT: Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. J Immunol 166: 4534-4542, 2001.
41. Gourley TS and Chang CH: Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J Immunol 166: 2917-2921, 2001.
42. Carrington PE, Sandu C, Wei Y, Hill JM, Morisawa G, Huang T, Gavathiotis E, Wei Y and Werner MH: The structure of FADD and its mode of interaction with procaspase-8. Mol Cell 22: 599-610, 2006.
43. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
44. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
45. de Vries JF, von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Willemze R, Falkenburg JH and Barge RM: Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. Haematologica 92: 1671-1678, 2007.